Seagen, Inc. announced that the Phase III ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival in patients with advanced classical Hodgkin lymphoma following treatment with ADCETRIS in combination with chemotherapy.
[Seagen, Inc.]
Sorry, but the selected Zotpress account can't be found.
